Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative - Fitch Research

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative - Fitch Research
Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative
Published Oct 02, 2018
2548 words — Published Oct 02, 2018
Price US$ 149.00  |  Buy this Report Now

About This Report

  
Brief Excerpt:

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative 02 Oct 2018 10:55 AM (EDT) Fitch Ratings-Chicago-02 October 2018: Fitch Ratings has affirmed Pfizer Inc.'s 'A+' rating with a Negative Rating Outlook. The rating actions apply to roughly...

  
Report Type:

Press Release

Company(ies)
Wyeth LLC , Pfizer Inc. , Pharmacia LLC
Ticker(s)
PFE
Issuer
Pharmacia Corp.
Format:
HTML HTML
Buy Now

Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

About the Author


Cite this Report

  
MLA:
Fitch Research. "Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative" Oct 02, 2018. Alacra Store. May 13, 2025. <http://www.alacrastore.com/fitch-credit-research/Fitch-Affirms-Pfizer-s-IDR-at-A-Outlook-Negative-1047554_pr_frame>
  
APA:
Fitch Research. (). Fitch Affirms Pfizer's IDR at 'A+'; Outlook Negative Oct 02, 2018. New York, NY: Alacra Store. Retrieved May 13, 2025 from <http://www.alacrastore.com/fitch-credit-research/Fitch-Affirms-Pfizer-s-IDR-at-A-Outlook-Negative-1047554_pr_frame>
  
US$ 149.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.